ストックスクリーナーアプリを入手
2.79
8.82%
-0.27
前日終値:
$3.06
開ける：
$3.07
24時間の取引高:
50,340
Relative Volume:
0.27
時価総額：
$14.74M
収益：
-
当期純損益:
$-33.08M
株価収益率:
-0.949
EPS:
-2.94
ネットキャッシュフロー:
$-25.68M
1週間 パフォーマンス:
-8.52%
1か月 パフォーマンス:
+2.57%
6か月 パフォーマンス:
+96.48%
1年 パフォーマンス:
+102.17%
1日の値動き範囲:
$2.795
$3.07
1週間の範囲:
$2.795
$3.2929
52週間の値動き範囲:
$0.8288
$3.855
Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile
名前
Chemomab Therapeutics Ltd Adr
セクター
電話
972-77-331-0156
住所
KIRYAT ATIDIM, BUILDING 7, TEL AVIV
CMMB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CMMB
Chemomab Therapeutics Ltd Adr
|
2.85 | 15.88M | 0 | -33.08M | -25.68M | -2.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.63 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.39 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.26 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
821.78 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.80 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Chemomab Therapeutics Ltd Adr Stock (CMMB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-13 | 開始されました | Maxim Group | Buy |
| 2024-05-06 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-12-19 | 再開されました | ROTH MKM | Buy |
Chemomab Therapeutics Ltd Adr (CMMB) 最新ニュース
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition - sharewise.com
Best Momentum Stocks to Buy for Oct. 23 - The Globe and Mail
New Strong Buy Stocks for Oct. 23: MQ, GES and More - Yahoo Finance
NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients - sharewise.com
Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis - sharewise.com
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up - The Globe and Mail
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan - sharewise.com
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy - sharewise.com
CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer - Yahoo Finance
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals - Zacks Investment Research
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain - sharewise.com
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder - Yahoo Finance
Chemomab Therapeutics (NASDAQ:CMMB) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza - sharewise.com
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - sharewise.com
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure - The Globe and Mail
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study - Yahoo Finance
Oppenheimer raises Chemomab stock price target to $25 on M&A potential By Investing.com - Investing.com South Africa
Oppenheimer raises Chemomab stock price target to $25 on M&A potential - Investing.com Nigeria
Chemomab Therapeutics price target raised to $25 from $10 at Oppenheimer - TipRanks
CMMB’s Market Whiplash: -34.81% YTD Decline, -15.11% Plunge in 30 Days - investchronicle.com
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy - sharewise
KURA Stock Rises More Than 15% This Past Week: Here's Why - The Globe and Mail
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study - sharewise
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study - Yahoo Finance
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - sharewise
RCKT Stock Tanks On Patient Death In Danon Disease Study - Barchart.com
RCKT Stock Tanks on Patient Death in Danon Disease Study - Yahoo Finance
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Yahoo Finance
Chemomab prepares for annual shareholder meeting By Investing.com - Investing.com India
Chemomab prepares for annual shareholder meeting - Investing.com
Chemomab Leadership Changes Signal Strategic Momentum Following Positive Clinical Results - Barchart.com
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial - Barchart.com
Microsoft Stock After Xbox Price Hike: Buy Or Hold? - Barchart.com
Should You Buy, Sell, Or Hold Nio Stock Amid Firefly Brand Launch? - Barchart.com
UBS Group Q1 Earnings & Revenues Dip Y/Y, Credit Loss Expenses Slip - Barchart.com
This ‘Strong Buy’ Robotaxi Stock Just Got A Huge Bump. Should You Buy Shares Now? - Barchart.com
Chemomab reports promising PSC treatment data - Investing.com
Chemomab Announces New Medical And Clinical Appointments - Barchart.com
Chemomab Therapeutics Ltd Adr (CMMB) 財務データ
収益
当期純利益
現金流量
EPS
0.29%
0.16%
大文字化:
|
ボリューム (24 時間):